{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:41:52Z","timestamp":1790876512415,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research"},{"name":"The University of Texas MD Anderson Cancer Center Internal Research Grant"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA190171"],"award-info":[{"award-number":["CA190171"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA190171"],"award-info":[{"award-number":["CA190171"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R120501"],"award-info":[{"award-number":["R120501"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03022-0","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:36:27Z","timestamp":1783326987000},"page":"1951-1960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-534X","authenticated-orcid":false,"given":"Hannah C.","family":"Beird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankaranarayanan","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Olguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-3235","authenticated-orcid":false,"given":"Tianyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-1801","authenticated-orcid":false,"given":"Jennifer L.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-5124","authenticated-orcid":false,"given":"Sandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latasha","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos R.","family":"Estecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-3562","authenticated-orcid":false,"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Gumbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"3022_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","volume":"73","author":"GS Guru Murthy","year":"2018","unstructured":"Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21\u201323.","journal-title":"Leuk Res"},{"key":"3022_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/bloodadvances.2019001260","volume":"4","author":"J Nomburg","year":"2020","unstructured":"Nomburg J, Bullman S, Chung SS, Togami K, Walker MA, Griffin GK, et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4:1006\u201311.","journal-title":"Blood Adv"},{"key":"3022_CR3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.2021011817","volume":"138","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Wilson N, Khoury J, Jain N, Daver N, Pierce S, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2022;138:1373\u20137.","journal-title":"Blood"},{"key":"3022_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MOH.0000000000000569","volume":"27","author":"K Sweet","year":"2020","unstructured":"Sweet K. Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment. Curr Opin Hematol. 2020;27:103\u20137.","journal-title":"Curr Opin Hematol"},{"key":"3022_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","volume":"5","author":"F Renosi","year":"2021","unstructured":"Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, et al. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv. 2021;5:1540\u201351.","journal-title":"Blood Adv"},{"key":"3022_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2013.283","volume":"28","author":"J Menezes","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28:823\u20139.","journal-title":"Leukemia"},{"key":"3022_CR7","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","volume":"35","author":"K Batta","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. 2021;35:3299\u2013303.","journal-title":"Leukemia"},{"key":"3022_CR8","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41375-024-02305-8","volume":"38","author":"S Denker","year":"2024","unstructured":"Denker S, Kunstner A, Schwarting J, Witte HM, Bernard V, Stolting S, et al. Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone. Leukemia. 2024;38:1858\u201361.","journal-title":"Leukemia"},{"key":"3022_CR9","doi-asserted-by":"crossref","unstructured":"Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, et al. Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm. Cancers. 2021;13:5888.","DOI":"10.3390\/cancers13235888"},{"key":"3022_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.18632\/oncotarget.28742","volume":"16","author":"F Fei","year":"2025","unstructured":"Fei F, Telatar M, Tomasian V, Chang L, Danilova O, Arias-Stella J, et al. Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: a single institution experience. Oncotarget. 2025;16:495\u2013507.","journal-title":"Oncotarget"},{"key":"3022_CR11","first-page":"264","volume":"200","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hsi ED, Crane GM, Cheng Y-W. Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): an institutional experience and review of literature. eJHaem. 2023;200:264\u20135.","journal-title":"eJHaem"},{"key":"3022_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0262-0","volume":"9","author":"HC Beird","year":"2019","unstructured":"Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9:99.","journal-title":"Blood Cancer J"},{"key":"3022_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.immuni.2015.07.009","volume":"43","author":"A Bunin","year":"2015","unstructured":"Bunin A, Sisirak V, Ghosh HS, Grajkowska LT, Hou ZE, Miron M, et al. Protein tyrosine phosphatase PTPRS is an inhibitory receptor on human and murine plasmacytoid dendritic cells. Immunity. 2015;43:277\u201388.","journal-title":"Immunity"},{"key":"3022_CR14","doi-asserted-by":"crossref","unstructured":"Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2021;12:522\u201341.","DOI":"10.1158\/2159-8290.CD-20-1513"},{"key":"3022_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809414","volume":"13","author":"EAK DePasquale","year":"2022","unstructured":"DePasquale EAK, Ssozi D, Ainciburu M, Good J, Noel J, Villanueva MA, et al. Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. Front Immunol. 2022;13:809414.","journal-title":"Front Immunol"},{"key":"3022_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"},{"key":"3022_CR17","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40:3032\u201336.","DOI":"10.1200\/JCO.22.00034"},{"key":"3022_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.","journal-title":"Nat Commun"},{"key":"3022_CR19","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387.e3529.","journal-title":"Cell"},{"key":"3022_CR20","unstructured":"Tickle T, Tirosh I, Georgescu C, Brown M, Haas B (2019). inferCNV of the Trinity CTAT Project.. Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. https:\/\/github.com\/broadinstitute\/inferCNV."},{"key":"3022_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.577152","volume":"11","author":"LM Chunn","year":"2020","unstructured":"Chunn LM, Nefcy DC, Scouten RW, Tarpey RP, Chauhan G, Lim MS, et al. Mastermind: a comprehensive genomic association search engine for empirical evidence curation and genetic variant interpretation. Front Genet. 2020;11:577152.","journal-title":"Front Genet"},{"key":"3022_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/bloodadvances.2024013423","volume":"9","author":"S Kannan","year":"2025","unstructured":"Kannan S, Li Y, Baran N, Yang X, Ghotbaldini S, Zhang Tatarata Q, et al. Antileukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025;9:473\u201387.","journal-title":"Blood Adv"},{"key":"3022_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 2013;14:128.","journal-title":"BMC Bioinforma"},{"key":"3022_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"3022_CR25","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood-2017-11-817296","volume":"131","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, et al. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018;131:1820\u201332.","journal-title":"Blood"},{"key":"3022_CR26","doi-asserted-by":"crossref","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, et al. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently shares a clonal origin in elderly patients. Leukemia 2022;36:1343\u201350.","DOI":"10.1038\/s41375-022-01538-9"},{"key":"3022_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2021011354","volume":"139","author":"F Yang","year":"2022","unstructured":"Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022;139:1208\u201321.","journal-title":"Blood"},{"key":"3022_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10767","volume":"7","author":"J Merlevede","year":"2016","unstructured":"Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.","journal-title":"Nat Commun"},{"key":"3022_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cas.14688","volume":"112","author":"H Kunimoto","year":"2021","unstructured":"Kunimoto H, Nakajima H. TET2: A cornerstone in normal and malignant hematopoiesis. Cancer Sci. 2021;112:31\u201340.","journal-title":"Cancer Sci"},{"key":"3022_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41586-024-07969-x","volume":"634","author":"Z Zou","year":"2024","unstructured":"Zou Z, Dou X, Li Y, Zhang Z, Wang J, Gao B, et al. RNA m(5)C oxidation by TET2 regulates chromatin state and leukaemogenesis. Nature. 2024;634:986\u201394.","journal-title":"Nature"},{"key":"3022_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","volume":"618","author":"GK Griffin","year":"2023","unstructured":"Griffin GK, Booth CAG, Togami K, Chung SS, Ssozi D, Verga JA, et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023;618:834\u201341.","journal-title":"Nature"},{"key":"3022_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.0105-2896.2010.00908.x","volume":"235","author":"IS Afonina","year":"2010","unstructured":"Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL\/NK protease granzyme B. Immunol Rev. 2010;235:105\u201316.","journal-title":"Immunol Rev"},{"key":"3022_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0092-8674(00)81458-0","volume":"93","author":"P Pierre","year":"1998","unstructured":"Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 1998;93:1135\u201345.","journal-title":"Cell"},{"key":"3022_CR34","doi-asserted-by":"publisher","first-page":"8128","DOI":"10.4049\/jimmunol.179.12.8128","volume":"179","author":"DJ Lee","year":"2007","unstructured":"Lee DJ, Sieling PA, Ochoa MT, Krutzik SR, Guo B, Hernandez M, et al. LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol. 2007;179:8128\u201336.","journal-title":"J Immunol"},{"key":"3022_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxicon.2015.04.012","volume":"116","author":"L Schnell","year":"2016","unstructured":"Schnell L, Dmochewitz-Kuck L, Feigl P, Montecucco C, Barth H. Thioredoxin reductase inhibitor auranofin prevents membrane transport of diphtheria toxin into the cytosol and protects human cells from intoxication. Toxicon. 2016;116:23\u201328.","journal-title":"Toxicon"},{"key":"3022_CR36","doi-asserted-by":"crossref","unstructured":"Stafford WC, Peng X, Olofsson MH, Zhang X, Luci DK, Lu L, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018;10:eaaf7444.","DOI":"10.1126\/scitranslmed.aaf7444"},{"key":"3022_CR37","doi-asserted-by":"crossref","unstructured":"Zdzalik-Bielecka D, Poswiata A, Kozik K, Jastrzebski K, Schink KO, Brewinska-Olchowik M, et al. The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion. Proc Natl Acad Sci USA. 2021;118:e2024596118.","DOI":"10.1073\/pnas.2024596118"},{"key":"3022_CR38","doi-asserted-by":"crossref","unstructured":"Beird HC, Yin CC, Khoury JD, Pierce SR, Abbas HA, Zhao L, et al. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023;7:2000-3.","DOI":"10.1182\/bloodadvances.2022007879"},{"key":"3022_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09710-z","volume":"10","author":"S Kubota","year":"2019","unstructured":"Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, et al. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nat Commun. 2019;10:1653.","journal-title":"Nat Commun"},{"key":"3022_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01816-0","volume":"17","author":"Z Yu","year":"2025","unstructured":"Yu Z, Zhong L, Tang W, Zhang W, Lin T, Zhu W, et al. TET2-mediated 5-hydroxymethylcytosine of TXNIP promotes cell cycle arrest in systemic anaplastic large cell lymphoma. Clin Epigenet. 2025;17:10.","journal-title":"Clin Epigenet"},{"key":"3022_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.dnarep.2016.05.031","volume":"43","author":"E Mahfoudhi","year":"2016","unstructured":"Mahfoudhi E, Talhaoui I, Cabagnols X, Della Valle V, Secardin L, Rameau P, et al. TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. DNA Repair. 2016;43:78\u201388.","journal-title":"DNA Repair"},{"key":"3022_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2019.00210","volume":"9","author":"Y Feng","year":"2019","unstructured":"Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210.","journal-title":"Front Oncol"},{"key":"3022_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3324\/haematol.2018.202093","volume":"104","author":"MR Sapienza","year":"2019","unstructured":"Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica. 2019;104:729\u201337.","journal-title":"Haematologica"},{"key":"3022_CR44","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41375-024-02240-8","volume":"38","author":"A Kunstner","year":"2024","unstructured":"Kunstner A, Schwarting J, Witte HM, Xing P, Bernard V, Stolting S, et al. Genome-wide DNA methylation analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features. Leukemia. 2024;38:1086\u201398.","journal-title":"Leukemia"},{"key":"3022_CR45","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/S0021-9258(18)53890-4","volume":"268","author":"E Papini","year":"1993","unstructured":"Papini E, Rappuoli R, Murgia M, Montecucco C. Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. J Biol Chem. 1993;268:1567\u201374.","journal-title":"J Biol Chem"},{"key":"3022_CR46","doi-asserted-by":"crossref","unstructured":"Ott L, Moller J, Burkovski A. Interactions between the Re-emerging pathogen Corynebacterium diphtheriae and host cells. Int J Mol Sci. 2022;23:3298.","DOI":"10.3390\/ijms23063298"},{"key":"3022_CR47","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1083\/jcb.200210028","volume":"160","author":"R Ratts","year":"2003","unstructured":"Ratts R, Zeng H, Berg EA, Blue C, McComb ME, Costello CE, et al. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. J Cell Biol. 2003;160:1139\u201350.","journal-title":"J Cell Biol"},{"key":"3022_CR48","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1172\/JCI128571","volume":"129","author":"K Togami","year":"2019","unstructured":"Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Investig. 2019;129:5005\u201319.","journal-title":"J Clin Investig"},{"key":"3022_CR49","doi-asserted-by":"publisher","first-page":"E171","DOI":"10.1002\/ajh.26146","volume":"96","author":"BJ Ball","year":"2021","unstructured":"Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, et al. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. Am J Hematol. 2021;96:E171\u2013E175.","journal-title":"Am J Hematol"},{"key":"3022_CR50","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26731","volume":"97","author":"D Rivera","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022;97:1599\u2013606.","journal-title":"Am J Hematol"},{"key":"3022_CR51","doi-asserted-by":"publisher","first-page":"66087","DOI":"10.18632\/oncotarget.19798","volume":"8","author":"JD Zhou","year":"2017","unstructured":"Zhou JD, Yao DM, Li XX, Zhang TJ, Zhang W, Ma JC, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8:66087\u201397.","journal-title":"Oncotarget"},{"key":"3022_CR52","doi-asserted-by":"crossref","unstructured":"Sindhu S, Kochumon S, Shenouda S, Wilson A, Al-Mulla F, Ahmad R. The cooperative induction of CCL4 in human monocytic cells by TNF-alpha and palmitate requires MyD88 and involves MAPK\/NF-kappaB signaling pathways. Int J Mol Sci. 2019;20:4658.","DOI":"10.3390\/ijms20184658"},{"key":"3022_CR53","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842\u20137.","journal-title":"Science"},{"key":"3022_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","volume":"23","author":"Z Cai","year":"2018","unstructured":"Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018;23:833\u2013849.e835.","journal-title":"Cell Stem Cell"},{"key":"3022_CR55","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood.2022015384","volume":"140","author":"M Agrawal","year":"2022","unstructured":"Agrawal M, Niroula A, Cunin P, McConkey M, Shkolnik V, Kim PG, et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022;140:1094\u2013103.","journal-title":"Blood"},{"key":"3022_CR56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","volume":"123","author":"S Sano","year":"2018","unstructured":"Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123:335\u201341.","journal-title":"Circ Res"},{"key":"3022_CR57","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41577-019-0185-9","volume":"19","author":"JJ Bernard","year":"2019","unstructured":"Bernard JJ, Gallo RL, Krutmann J. Photoimmunology: how ultraviolet radiation affects the immune system. Nat Rev Immunol. 2019;19:688\u2013701.","journal-title":"Nat Rev Immunol"},{"key":"3022_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188\u2013202.","journal-title":"Br J Haematol"},{"key":"3022_CR59","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood.2020008745","volume":"137","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N. Targeting the p-D-C: easy as C-D-1-2-3? Blood. 2021;137:1277\u20138.","journal-title":"Blood"},{"key":"3022_CR60","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","volume":"8","author":"AA Lane","year":"2024","unstructured":"Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024;8:591\u2013602.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03022-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:01:48Z","timestamp":1787684508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3022"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03022-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NP: Consultancy\/Scientific Advisory Board\/Speaking: Pacylex Pharmaceuticals, Astellas Pharma US, Aplastic Anemia & MDS International Foundation, CareDx, ImmunoGen, Inc, Bristol-Myers Squibb Co., Cimeio Therapeutics AG, EUSA Pharma, Menarini Group, Blueprint Medicines, CTI BioPharma, ClearView Healthcare Partners, Novartis Pharmaceutical, Neopharm, Celgene Corporation, AbbVie Pharmaceuticals, Pharma Essentia, Curio Science, DAVA Oncology, Imedex, Intellisphere, CancerNet, Harborside Press, Karyopharm, Aptitude Health, Medscape, Magdalen Medical Publishing, Morphpsys, OncLive, CareDx, Patient Power, Physician Education Resource (PER), PeerView Insitute for Medical Education; Research (grant): United States Department of Defense, National Institute of Health\/National Cancer Institute (NIH\/NCI); Membership on an entity\u2019s Board of Directors\/Management: Dan\u2019s House of Hope; Leadership: ASH Committee on Communications, ASCO Cancer.Net Editorial Board; Licenses: Karger. MK: Research Funding from AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision, Rafael, Sanofi, and Menarini Group. Advisory\/Consulting for AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue Therapeutics, F Hoffman La-Roche, Genentech, Gilead, Janssen, Legend, MEI Pharma, Redona, Sanofi, Sellas, Menarini Group, Vincerx. Stock options\/Royalties in Reata Pharmaceutical (IP). Patents with Novartis, Eli Lilly, and Reata Pharmaceuticals. JC, AO, JLC, and CB are full-time employees at Menarini Stemline.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study is approved under the Institutional Review Boards at Moffit Cancer Center and Research Institute (13474), City of Hope (20132099), Roswell Park Comprehensive Cancer Center (PH259514), and The University of MD Anderson Cancer Center (2013-0979). Permission to collect trial samples was obtained through informed consent from each participating institutional review board.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}